Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AstraZeneca plc (AZN) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance

AstraZeneca plcTrade
iShares 1 3 Year Treasury Bond ETFTrade

Price performance (Past 24H)

Key statistics

AstraZeneca plc vs iShares 1 3 Year Treasury Bond ETF — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while iShares 1 3 Year Treasury Bond ETF trades at $81.93. The key difference: AstraZeneca plc pays a 2.01% dividend while iShares 1 3 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals.

AZNSHY
Market Cap
$248.14B
Sector
HealthFixed Income
52-Week High
$209.48$83.18
52-Week Low
$147.06$81.77
Enterprise Value
$275.41B
Dividend Yield
2.01%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AstraZeneca plc

AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.

Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.

iShares 1 3 Year Treasury Bond ETF

SHY, the iShares 1-3 Year Treasury Bond ETF, trades at $81.92, up 0.08% on the day. Technical indicators are bearish overall, with moving averages signaling sell pressure, while oscillators remain neutral. Recent news highlights institutional buying interest amid fluctuating Treasury yields driven by inflation data and geopolitical tensions.

The outlook for SHY is influenced by Federal Reserve policy expectations and inflation trends. Opportunities include its role as a short-duration bond haven during volatility, but risks involve rising yields pressuring prices and macroeconomic uncertainty. Investors should weigh interest rate sensitivity against current institutional accumulation.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AstraZeneca plc

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Read more on AZN

About iShares 1 3 Year Treasury Bond ETF

SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.

Read more on SHY